Mark Raza has served as the Principal Deputy Chief Counsel since 2011 as well as in 2005-2006 and 2001. He leads the Office of the Chief Counsel COVID-19 emergency team and has played an integral role in the agency’s pandemic response. A member of OCC since 1990, Mr. Raza has broad experience in the work that OCC does with particular expertise in the law governing biological products, devices, emergency preparedness and response, information disclosure, human subject protection, and combination products, among others. He has successfully represented the FDA in both civil and criminal litigation. He served as the Acting Deputy Center Director for Policy in the Center for Devices and Radiological Health and is a graduate of Harvard Law School and Boston College.

More Information

• FDA Leadership Profiles